Pilot trial of sunitinib therapy in patients with von Hippel–Lindau disease

Background: Von Hippel–Lindau (VHL) disease induces vascular neoplasms in multiple organs. We evaluated the safety and efficacy of sunitinib in VHL patients and examined the expression of candidate receptors in archived tissue. Methods: Patients with VHL were given four cycles of 50 mg sunitinib dai...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Ann Oncol
Hoofdauteurs: Jonasch, E., McCutcheon, I. E., Waguespack, S. G., Wen, S., Davis, D. W., Smith, L. A., Tannir, N. M., Gombos, D. S., Fuller, G. N., Matin, S. F.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2011
Onderwerpen:
Original Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4542805/
https://ncbi.nlm.nih.gov/pubmed/22105611
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdr011
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items